A RANDOMIZED, BLINDED, PLACEBO-CONTROLLED, DOSE FINDING STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE ORAL THROMBOPOIETIN RECEPTOR AGONIST, ELTROMBOPAG, ADMINISTERED TO SUBJECTS WITH ACUTE MYELOGENOUS LEUKAEMIA (AML) RECEIVING INDUCTION CHEMOTHERAPY
- Registry ID
- TRC117146
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- NOVARTIS PHARMACEUTICALS CANADA INC
- Start date
- 2014-05-08
- Last update
- 2013-07-04
Conditions
- ACUTE MYELOGENOUS LEUKEMIA
Related clinical trials
- A PHASE 1/2 FIRST IN HUMAN STUDY OF THE MENIN-MLL (KMT2A) INHIBITOR KO 539 IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ENTOSPLETINIB IN COMBINATION WITH INTENSIVE INDUCTION AND CONSOLIDATION CHEMOTHERAPY IN ADULTS WITH NEWLY DIAGNOSED NUCLEOPHOSMIN 1-MUTATED ACUTE MYELOID LEUKEMIA
- A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA
- A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG-221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION.
- PHASE I STUDY OF AUTOLOGOUS ACUTE MYELOGENOUS LEUKEMIA (AML) CELLS CONTAINING LENTIVIRUS ENGINEERING EXPRESSION OF IL-12
- RISK-STRATIFIED THERAPY FOR ACUTE MYELOID LEUKEMIA IN DOWN SYNDROME
View on source registry